| Bioactivity | DC-U4106 is a USP8 targeting inhibitor with the Kdvalue of 4.7 μM and the IC50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα. DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer[1]. |
| Invitro | DC-U4106 (1.2-45.2 μM) inhibits USP8 and USP2 with the IC50 values of 1.2 μM and 58.4 μM, respectively, and no activity in USP7[1]. DC-U4106 (0-7 μM, 24 hours) reduces mRNA levels of ERα and PR[1].DC-U4106 (0-5 μM, 24 hours) can regulate the RTK pathway related proteins and the expression of ERα and PR proteins[1].DC-U4106 (0-5 μM, 12 hours) can induce apoptosis and inhibit cell proliferation[1]. Western Blot Analysis[1] Cell Line: |
| Name | DC-U4106 |
| CAS | 2410534-62-0 |
| Formula | C29H27N5O5 |
| Molar Mass | 525.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
DC-U4106
CAS: 2410534-62-0 F: C29H27N5O5 W: 525.56
DC-U4106 is a USP8 targeting inhibitor with the Kdvalue of 4.7 μM and the IC50 value of 1.2 μM. DC-U4106 can target th
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.